COMMUNIQUÉS West-GlobeNewswire

LIDDS invited to speak at Formulation and Drug Delivery Congress in London
25/04/2019
Director of Pharmaceutical R&D, Stefan Grudén, has been invited to present at the Annual Formulation and Drug Delivery Congress being held in London on 29-30 April. This annual congress is an important event for [...]
Financière de Tubize SA : Approbation du dividende
25/04/2019
Communiqué de presse FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: aspijcke, directeur, aspijcke@icloud.com Approbation du dividende Information réglementée 24 avril 2019 L'assemblée générale [...]
Biocartis Group NV: BIOCARTIS Q1 2019 BUSINESS UPDATE
25/04/2019
PRESS RELEASE : REGULATED INFORMATION Thursday 25 April 2019, 07:00 CEST BIOCARTIS Q1 2019 BUSINESS UPDATE Mechelen, Belgium , 25 April 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular [...]
ACACIA PHARMA ANNOUNCES POSITIVE PHASE 3 BARHEMSYS® RESCUE TREATMENT DATA TO BE PRESENTED AT THE ANNUAL CONGRESS OF ENHANCED RECOVERY AND PERIOPERATIVE MEDICINE
25/04/2019
Cambridge, UK and Indianapolis, US – 25 April 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that additional data and analyses from its positive Phase 3 clinical trial of [...]
Bone Therapeutics announces publication of Annual Report 2018 and Extraordinary General Meeting on 23 May 2019
25/04/2019
Regulated information Gosselies, Belgium, 25 April 2019, 7 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics annonce la publication de son Rapport Annuel 2018 et la tenue d’une Assemblée Générale Extraordinaire le 23 mai 2019
25/04/2019
Information réglementée Gosselies, Belgique, le 25 avril 2019, 7h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE, éligible PEA-PME), société de thérapie cellulaire osseuse qui répond à d’importants [...]
Active Biotech AB - Interim report January - March 2019
25/04/2019
First quarter in brief Active Biotech's partner NeoTX entered clinical collaboration with AstraZeneca to evaluate ANYARA ("naptumumab") in combination with IMFINZI® (durvalumab) in the upcoming Phase Ib/II study On 1 [...]
Constitutive meeting of Biohit Oyj’s Board of Directors
25/04/2019
Biohit Oyj: Other information disclosed according to the rules of the Exchange April 25, 2019 at 9:30 am local time (EEST) Biohit Oyj’s Board of Directors has in its meeting yesterday elected Mr Osmo Suovaniemi as the [...]
Q1 conference call
25/04/2019
Vistin Pharma ASA Quarterly Report – Q1 2019 25 April 2019, 08:30 CET Telephone conference: Confirmation Code:.............. 7481935 International Dial-In: ............ +44 (0) 2071 928000 Norway, Oslo: 23960264 United [...]
Acarix publishes the annual report for 2018
25/04/2019
Press release Malmö, April 25, 2019 Acarix publishes the annual report for 2018 Today, Thursday April 25, Acarix is publishing its Annual Report for 2018 on the company website www.acarix.com . The Annual Report is also [...]
Immunicum AB (publ) Interim Report January - March 2019
25/04/2019
Press Release 25 April 2019 Immunicum AB (publ) Interim Report January - March 2019 Preparations for Upcoming Clinical Data in the MERECA and GIST Studies and First Patient Treated in the ILIAD Study Significant Events [...]
Financière de Tubize SA : Approval of dividend
25/04/2019
Press release FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, general manager, aspijcke@icloud.com Approval of dividend Regulated information 24 April 2019 The general [...]
First quarter 2019 financial results
25/04/2019
Vistin Pharma ASA: First quarter 2019 financial results Oslo, Norway, 25 April 2019 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter of 2019. The revenues for [...]
Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock
25/04/2019
EMERYVILLE, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing of its underwritten public offering of 6,500,000 shares of common stock at a public offering [...]
Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
24/04/2019
COPENHAGEN, Denmark, April 24, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced [...]
R1 RCM to Release First Quarter 2019 Results on May 9
24/04/2019
CHICAGO, April 24, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced it expects to release [...]
Assertio Therapeutics to Report First Quarter 2019 Financial Results After The Close of Markets on Wednesday, May 8, 2019
24/04/2019
LAKE FOREST, Ill., April 24, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019, after the close of [...]
Integrated Cannabis Company Announces $5,000,000 Non-Brokered Private Placement
24/04/2019
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 24, 2019 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, [...]
Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
24/04/2019
Post-hoc analysis published in Advances in Therapy indicated patients with unilateral knee osteoarthritis experienced significant and durable reductions in pain with ZILRETTA vs. immediate-release triamcinolone [...]

Pages